BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 35810638)

  • 21. Standard triple therapy for Helicobacter pylori infection in China: a meta-analysis.
    Wang B; Lv ZF; Wang YH; Wang H; Liu XQ; Xie Y; Zhou XJ
    World J Gastroenterol; 2014 Oct; 20(40):14973-85. PubMed ID: 25356059
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy.
    Suzuki S; Gotoda T; Kusano C; Iwatsuka K; Moriyama M
    Am J Gastroenterol; 2016 Jul; 111(7):949-56. PubMed ID: 27185079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose dual therapy versus bismuth-containing quadruple therapy for the eradication of Helicobacter pylori: A systematic review and meta-analysis.
    Wang H; Kong QZ; Li YY; Yang XY; Zuo XL
    J Dig Dis; 2024 Mar; 25(3):163-175. PubMed ID: 38577962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: A systematic review and meta-analysis.
    Zhou BG; Jiang X; Ding YB; She Q; Li YY
    Helicobacter; 2024; 29(1):e13040. PubMed ID: 37983865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms of
    Sue S; Maeda S
    Gut Liver; 2021 Nov; 15(6):799-810. PubMed ID: 33850058
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Potassium-Competitive Acid Blocker-Based Regimen as Second-Line Therapy Improves Helicobacter pylori Eradication.
    Nabeta H; Shinozaki S; Abe Y; Koyanagi R; Nakamichi T; Kobayashi Y; Lefor AK; Hirashima H
    Digestion; 2020; 101(3):332-338. PubMed ID: 30991394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Helicobacter pylori eradication with moxifloxacin-containing therapy following failed first-line therapies in South Korea.
    Kang KK; Lee DH; Oh DH; Yoon H; Shin CM; Park YS; Kim N; Jung HC
    World J Gastroenterol; 2014 Jun; 20(22):6932-8. PubMed ID: 24944485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori.
    Li M; Oshima T; Horikawa T; Tozawa K; Tomita T; Fukui H; Watari J; Miwa H
    Helicobacter; 2018 Aug; 23(4):e12495. PubMed ID: 29873436
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of Probiotic Supplementation Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Controlled Trials.
    Lü M; Yu S; Deng J; Yan Q; Yang C; Xia G; Zhou X
    PLoS One; 2016; 11(10):e0163743. PubMed ID: 27723762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative study: Vonoprazan and proton pump inhibitors in
    Sakurai K; Suda H; Ido Y; Takeichi T; Okuda A; Hasuda K; Hattori M
    World J Gastroenterol; 2017 Jan; 23(4):668-675. PubMed ID: 28216974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose dual therapy versus bismuth-containing quadruple therapy for the treatment of
    Zhang C; Zhang J; Cheng YJ
    Saudi J Gastroenterol; 2023; 29(2):88-94. PubMed ID: 36960527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hybrid, sequential and concomitant therapies for Helicobacter pylori eradication: A systematic review and meta-analysis.
    Song ZQ; Zhou LY
    World J Gastroenterol; 2016 May; 22(19):4766-75. PubMed ID: 27217708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of
    Jung YS; Kim S; Kim HY; Noh SJ; Park JH; Sohn CI; Park CH
    Gut Liver; 2023 Sep; 17(5):711-721. PubMed ID: 36510776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PPI-amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta-analysis.
    Gao CP; Zhang D; Zhang T; Wang JX; Han SX; Graham DY; Lu H
    Helicobacter; 2020 Aug; 25(4):e12692. PubMed ID: 32314468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of genotypic susceptibility-guided tailored therapy for Helicobacter pylori infection: A systematic review and single arm meta-analysis.
    Lin K; Huang L; Wang Y; Li K; Ye Y; Yang S; Li A
    Helicobacter; 2023 Dec; 28(6):e13015. PubMed ID: 37634236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sequential or concomitant therapy for eradication of Helicobacter pylori infection: A systematic review and meta-analysis.
    Kim JS; Park SM; Kim BW
    J Gastroenterol Hepatol; 2015 Sep; 30(9):1338-45. PubMed ID: 25867718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reverse hybrid therapy for Helicobacter pylori eradication: A systematic review and meta-analysis.
    Hu Y; Ouyang Y; Zhu Y; Lu NH
    Helicobacter; 2021 Apr; 26(2):e12784. PubMed ID: 33534148
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ten-day high-dose proton pump inhibitor triple therapy versus sequential therapy for Helicobacter pylori eradication.
    Auesomwang C; Maneerattanaporn M; Chey WD; Kiratisin P; Leelakusolwong S; Tanwandee T
    J Gastroenterol Hepatol; 2018 Nov; 33(11):1822-1828. PubMed ID: 29804294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.
    Luther J; Higgins PD; Schoenfeld PS; Moayyedi P; Vakil N; Chey WD
    Am J Gastroenterol; 2010 Jan; 105(1):65-73. PubMed ID: 19755966
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amoxicillin-vonoprazan dual therapy for Helicobacter pylori eradication: A systematic review and meta-analysis.
    Ouyang Y; Wang M; Xu YL; Zhu Y; Lu NH; Hu Y
    J Gastroenterol Hepatol; 2022 Sep; 37(9):1666-1672. PubMed ID: 35716370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.